• FITC-Concanavalin A (ConA) Conjugate: Technical Use and Prot

  2026-08-03

  FITC-Concanavalin A (ConA) Conjugate enables direct, fluorescence-based detection of α-D-glucose and α-D-mannose on cell surfaces for immunofluorescence and flow cytometry workflows. It is specifically optimized for carbohydrate detection in glycobiology research, and should not be applied to non-carbohydrate targets or outside its defined stability conditions.

• I-BET-762: BET Inhibitor Applications in Ferroptosis Researc

  2026-08-03

  I-BET-762 stands out as a nanomolar-selective BET inhibitor, empowering researchers to synergize ferroptosis induction with precise epigenetic modulation. Backed by recent evidence, it reveals new mechanistic links between ROS, FSP1, and cancer cell death, with robust workflows for inflammation and transcriptional regulation studies.

• PF-573228: FAK Inhibitor Workflows for Mechanotransduction S

  2026-08-02

  PF-573228 enables precise control of FAK signaling in cell-based assays, driving insights into mechanotransduction, cancer migration, and tissue engineering. This guide translates recent breakthroughs into practical workflows, troubleshooting, and optimization strategies for researchers focused on FAK-dependent pathways.

• Iptacopan (LNP023): Translating Alternative Pathway Inhibiti

  2026-08-01

  This article explores the mechanistic and translational impact of Iptacopan (LNP023), a selective oral complement factor B inhibitor, for researchers targeting alternative pathway dysregulation. We connect preclinical and clinical data, competitive context, and emerging workflow strategies, with actionable guidance for translational research teams.

• RNA Pol II Inhibition Triggers Apoptosis Independent of Tran

  2026-07-31

  Harper et al. (2025) demonstrate that cell death from RNA polymerase II (Pol II) inhibition is not due to loss of transcription, but rather to the depletion of hypophosphorylated RNA Pol IIA and a specific apoptotic signaling cascade. This finding redefines mechanistic understanding in DNA damage response and cancer biology research, with implications for drug development and the interpretation of cytotoxicity in transcription-targeting therapies.

• Q-VD-OPh: Pan-Caspase Inhibitor for Advanced Apoptosis Resea

  2026-07-31

  Q-VD-OPh empowers researchers to dissect apoptosis and caspase activity with unmatched selectivity and brain permeability. Its robust inhibition profile supports workflows from neurodegeneration models to enhancing cell viability after cryopreservation, as well as enabling precision control in emerging virology assays.

• RBD-Targeted mRNA Vaccines Show Superior MERS-CoV Protection

  2026-07-30

  A recent study compared mRNA vaccines encoding either the full spike (S) protein or only the receptor-binding domain (RBD) of MERS-CoV, finding that RBD-mRNA produced stronger and broader neutralizing antibody responses and more durable protection in a mouse model. These findings guide rational vaccine design and highlight the importance of RNA stability and modification strategies for next-generation mRNA-based interventions.

• MLKL Polymerization Drives Lysosomal Cathepsin B in Necropto

  2026-07-30

  The referenced study reveals that MLKL polymerization at lysosomal membranes induces lysosomal membrane permeabilization (LMP), resulting in the cytosolic release of cathepsin B and subsequent necroptotic cell death. These findings clarify the mechanistic sequence linking MLKL activity, lysosomal disruption, and regulated cell death, with direct implications for targeting lysosomal enzymes in experimental models.

• WNT5a/GSK3/β-catenin Axis Regulates Muscle FAP Adipogenesis

  2026-07-29

  This study uncovers the central role of the WNT5a/GSK3/β-catenin signaling axis in controlling adipogenesis of skeletal muscle fibro/adipogenic progenitors (FAPs), offering new mechanistic understanding of muscle regeneration and fat infiltration in myopathies. The findings suggest that targeting this pathway could provide novel strategies to mitigate muscle degeneration.

• Doxycycline: Tetracycline Antibiotic Workflows in Cancer Res

  2026-07-29

  Doxycycline’s dual role as a tetracycline antibiotic and metalloproteinase inhibitor is reshaping cancer research and advanced assay design. Explore optimized protocols, troubleshooting insights, and innovative applications that maximize the reproducibility and impact of APExBIO’s high-purity Doxycycline (SKU: BA1003).

• Iptacopan (LNP023): Defining Precision in Translational Comp

  2026-07-28

  Explore how Iptacopan (LNP023) is reshaping strategic decisions in complement activation research. This article provides mechanistic depth, real-world assay guidance, and a vision for translational researchers navigating the evolving landscape of alternative pathway inhibition.

• Dissecting Drug Responses: Enhanced In Vitro Cancer Assays

  2026-07-28

  Schwartz's dissertation introduces a dual-metric approach for evaluating anti-cancer drug responses in vitro, separating proliferation arrest from cell death for greater mechanistic clarity. This nuanced methodology improves the interpretability of drug screening results and supports more accurate preclinical assessment of candidate therapies.

• Fulvestrant (ICI 182,780): Applied Workflows in Breast Cance

  2026-07-27

  Fulvestrant (ICI 182,780) is a benchmark ER antagonist that enables reliable modeling of endocrine resistance and chemosensitization in breast cancer studies. This guide translates mechanistic insights and recent immunological advances into actionable experimental protocols, troubleshooting strategies, and advanced use-case recommendations.

• Fiber Density Regulates Collagen Heterogeneity in Annulus Fi

  2026-07-27

  This study demonstrates that scaffold fiber density can precisely direct annulus fibrosus cell (AFC) phenotypes and reconstruct collagen heterogeneity critical for intervertebral disc function. By leveraging mechanotransduction pathways—including RhoA-ROCK and Piezo1-mediated Ca2+ signaling—distinct scaffold microarchitectures enable region-specific matrix deposition, offering a blueprint for next-generation AF repair strategies.

• Haloprogin: Broad-Spectrum Topical Antifungal Benchmarks

  2026-07-26

  The 1970 reference study established Haloprogin (1,2,4-trichloro-5-((3-iodoprop-2-yn-1-yl)oxy)benzene) as a potent topical antifungal and selective antibacterial agent. Its unique spectrum and robust activity against dermatophytes, yeasts, and Gram-positive bacteria provide foundational guidance for experimental infection models and antifungal research protocols.

16569 records 1/1105 page Next 12345 下5页 Last page